11.54
price down icon3.27%   -0.39
after-market Dopo l'orario di chiusura: 12.11 0.57 +4.94%
loading
Precedente Chiudi:
$11.93
Aprire:
$11.76
Volume 24 ore:
440.75K
Relative Volume:
1.04
Capitalizzazione di mercato:
$617.72M
Reddito:
-
Utile/perdita netta:
$-156.39M
Rapporto P/E:
-3.1274
EPS:
-3.69
Flusso di cassa netto:
$-123.06M
1 W Prestazione:
-5.80%
1M Prestazione:
+1.27%
6M Prestazione:
-0.35%
1 anno Prestazione:
-2.70%
Intervallo 1D:
Value
$11.05
$11.76
Intervallo di 1 settimana:
Value
$11.05
$12.58
Portata 52W:
Value
$7.30
$15.50

Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile

Name
Nome
Kalvista Pharmaceuticals Inc
Name
Telefono
(857) 999-0075
Name
Indirizzo
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Name
Dipendente
0
Name
Cinguettio
@kalvista
Name
Prossima data di guadagno
2025-03-12
Name
Ultimi documenti SEC
Name
KALV's Discussions on Twitter

Confronta KALV con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
KALV
Kalvista Pharmaceuticals Inc
11.54 617.72M 0 -156.39M -123.06M -3.69
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-01-31 Iniziato JMP Securities Mkt Outperform
2025-01-07 Iniziato TD Cowen Buy
2024-12-18 Iniziato BofA Securities Buy
2020-06-15 Iniziato H.C. Wainwright Buy
2019-07-29 Iniziato SVB Leerink Outperform
2019-03-20 Iniziato Needham Buy
2018-10-30 Iniziato Jefferies Buy
2018-09-21 Iniziato Cantor Fitzgerald Overweight
2017-08-31 Iniziato BTIG Research Buy
Mostra tutto

Kalvista Pharmaceuticals Inc Borsa (KALV) Ultime notizie

pulisher
07:03 AM

KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference - Bluefield Daily Telegraph

07:03 AM
pulisher
07:00 AM

KalVista Set for Key Investor Presentation: What to Expect from Needham Conference - Stock Titan

07:00 AM
pulisher
Mar 27, 2025

KONFIDENT-KID trial of sebetralstat is now fully enrolled - Angioedema News

Mar 27, 2025
pulisher
Mar 26, 2025

Cantor Fitzgerald maintains Overweight on Kalvista shares By Investing.com - Investing.com Australia

Mar 26, 2025
pulisher
Mar 26, 2025

KalVista Pharmaceuticals enrols all subjects in hereditary angioedema drug trial - Yahoo Finance

Mar 26, 2025
pulisher
Mar 26, 2025

Stifel maintains Buy on Kalvista stock, price target steady at $39 By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Stifel maintains Buy on Kalvista stock, price target steady at $39 - Investing.com Australia

Mar 26, 2025
pulisher
Mar 26, 2025

Cantor Fitzgerald maintains Overweight on Kalvista shares - Investing.com India

Mar 26, 2025
pulisher
Mar 26, 2025

Kalvista stock holds as JMP reiterates $19 target By Investing.com - Investing.com Australia

Mar 26, 2025
pulisher
Mar 26, 2025

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Sold by Bank of New York Mellon Corp - Defense World

Mar 26, 2025
pulisher
Mar 26, 2025

Kalvista stock holds as JMP reiterates $19 target - Investing.com India

Mar 26, 2025
pulisher
Mar 25, 2025

KalVista completes enrollment for pediatric HAE trial By Investing.com - Investing.com South Africa

Mar 25, 2025
pulisher
Mar 25, 2025

KalVista Pharmaceuticals Completes Participant Enrollment Ahead of Schedule for Pediatric Hereditary Angioedema Trial - MarketScreener

Mar 25, 2025
pulisher
Mar 25, 2025

KalVista completes enrollment for pediatric HAE trial - Investing.com India

Mar 25, 2025
pulisher
Mar 25, 2025

KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial - Marketscreener.com

Mar 25, 2025
pulisher
Mar 25, 2025

Breakthrough Pediatric HAE Drug Trial Hits Major Milestone: Patient Demand Surges 50% - Stock Titan

Mar 25, 2025
pulisher
Mar 25, 2025

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives $23.80 Average Target Price from Analysts - Defense World

Mar 25, 2025
pulisher
Mar 21, 2025

(KALV) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Mar 21, 2025
pulisher
Mar 17, 2025

H.C. Wainwright maintains Buy on Kalvista, $20 target By Investing.com - Investing.com Canada

Mar 17, 2025
pulisher
Mar 17, 2025

KalVista Pharmaceuticals’ (KALV) Buy Rating Reiterated at HC Wainwright - Armenian Reporter

Mar 17, 2025
pulisher
Mar 17, 2025

H.C. Wainwright maintains Buy on Kalvista, $20 target - Investing.com India

Mar 17, 2025
pulisher
Mar 17, 2025

KalVista Pharmaceuticals Stock (KALV): Advancements in HAE Treatment and Regulatory Progress - Value the Markets

Mar 17, 2025
pulisher
Mar 16, 2025

HC Wainwright Reaffirms Buy Rating for KalVista Pharmaceuticals (NASDAQ:KALV) - Defense World

Mar 16, 2025
pulisher
Mar 15, 2025

Needham & Company LLC Reiterates “Buy” Rating for KalVista Pharmaceuticals (NASDAQ:KALV) - Defense World

Mar 15, 2025
pulisher
Mar 13, 2025

Buy Rating for KalVista Pharmaceuticals Driven by Anticipated FDA Approval and Strong Market Position - TipRanks

Mar 13, 2025
pulisher
Mar 13, 2025

Sebetralstat provides early, fast relief for HAE attacks: Data - Angioedema News Today

Mar 13, 2025
pulisher
Mar 13, 2025

Jefferies cuts Kalvista stock price target to $31 from $33 - Investing.com

Mar 13, 2025
pulisher
Mar 13, 2025

Jefferies cuts Kalvista stock price target to $31 from $33 By Investing.com - Investing.com Canada

Mar 13, 2025
pulisher
Mar 13, 2025

KalVista Pharmaceuticals Advances Sebetralstat for HAE - TipRanks

Mar 13, 2025
pulisher
Mar 12, 2025

KalVista Pharmaceuticals, Inc. SEC 10-Q Report - TradingView

Mar 12, 2025
pulisher
Mar 12, 2025

Kalvista Pharmaceuticals Inc reports results for the quarter ended January 31Earnings Summary - TradingView

Mar 12, 2025
pulisher
Mar 12, 2025

KALVISTA PHARMACEUTICALS Earnings Results: $KALV Reports Quarterly Earnings - Nasdaq

Mar 12, 2025
pulisher
Mar 12, 2025

KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update - Business Wire

Mar 12, 2025
pulisher
Mar 12, 2025

Reviewing KalVista Pharmaceuticals (NASDAQ:KALV) and Hillstream BioPharma (NASDAQ:HILS) - Defense World

Mar 12, 2025
pulisher
Mar 11, 2025

KalVista Pharmaceuticals CEO sells $79,827 in stock By Investing.com - Investing.com Australia

Mar 11, 2025
pulisher
Mar 10, 2025

KalVista Pharmaceuticals CEO sells $79,827 in stock - Investing.com

Mar 10, 2025
pulisher
Mar 10, 2025

KalVista Pharmaceuticals CEO Sells Shares to Cover Tax Obligations - TradingView

Mar 10, 2025
pulisher
Mar 10, 2025

KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and Progress for Sebetralstat in Hereditary Angioedema - The Bakersfield Californian

Mar 10, 2025
pulisher
Mar 07, 2025

Kalvista Pharmaceuticals Inc expected to post a loss of 87 cents a shareEarnings Preview - TradingView

Mar 07, 2025
pulisher
Mar 05, 2025

JMP Securities sets $19 target for Kalvista Pharmaceuticals stock - MSN

Mar 05, 2025
pulisher
Mar 05, 2025

JMP reiterates Kalvista stock with $19 target, sees market growth - MSN

Mar 05, 2025
pulisher
Mar 04, 2025

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Joplin Globe

Mar 04, 2025
pulisher
Mar 04, 2025

KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting - BioSpace

Mar 04, 2025
pulisher
Mar 03, 2025

Sebetralstat shows promise in treating HAE attacks By Investing.com - Investing.com Canada

Mar 03, 2025
pulisher
Mar 03, 2025

Sebetralstat shows promise in treating HAE attacks - Investing.com India

Mar 03, 2025

Kalvista Pharmaceuticals Inc Azioni (KALV) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
Capitalizzazione:     |  Volume (24 ore):